JSC Valenta Pharm Sustainability Profile
JSC Valenta Pharm, a prominent player in the pharmaceutical industry, is headquartered in Russia and operates extensively across various regions. Founded in 1997, the company has established itself as a leader in the development and production of high-quality generic medications and innovative pharmaceutical solutions. Valenta Pharm's core offerings include a diverse range of therapeutic products, particularly in the fields of oncology, cardiology, and neurology, distinguished by their commitment to quality and efficacy. The company has achieved significant milestones, including numerous certifications and partnerships that enhance its market position. With a focus on research and development, JSC Valenta Pharm continues to drive advancements in healthcare, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does JSC Valenta Pharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
JSC Valenta Pharm's score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
JSC Valenta Pharm's reported carbon emissions
JSC Valenta Pharm, headquartered in Russia, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is classified as a current subsidiary and inherits its climate commitments and data from its parent organization. However, there are no documented reduction targets or climate pledges available for JSC Valenta Pharm at this time. As a subsidiary, JSC Valenta Pharm's climate initiatives may align with broader corporate strategies from its parent company, but specific details regarding these initiatives or any emissions data are not provided. The lack of reported emissions and reduction targets suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. In the context of the pharmaceutical industry, companies are increasingly expected to adopt robust climate commitments and transparent reporting practices. JSC Valenta Pharm's current status reflects a need for enhanced focus on sustainability and emissions management to meet industry standards and stakeholder expectations.
How Carbon Intensive is JSC Valenta Pharm's Industry?
How Carbon Intensive is JSC Valenta Pharm's Location?
JSC Valenta Pharm's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
JSC Valenta Pharm has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
